Published in Cancer Res on August 31, 2010
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med (2013) 2.04
Inhibition of microRNA function by antimiR oligonucleotides. Silence (2012) 2.02
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A (2012) 1.72
Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology (2012) 1.62
Developing therapeutic microRNAs for cancer. Gene Ther (2011) 1.49
MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res (2011) 1.33
Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets (2012) 1.26
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget (2013) 1.22
MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol (2013) 1.22
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol (2013) 1.20
Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res (2013) 1.19
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19
Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect Immun (2011) 1.18
A novel real-time PCR assay of microRNAs using S-Poly(T), a specific oligo(dT) reverse transcription primer with excellent sensitivity and specificity. PLoS One (2012) 1.16
The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One (2012) 1.14
MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity. Neuro Oncol (2012) 1.12
siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12
Roles of microRNA on cancer cell metabolism. J Transl Med (2012) 1.11
MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat (2013) 1.11
miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One (2013) 1.09
Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther (2012) 1.07
MicroRNAs: new players in IBD. Gut (2014) 1.07
From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol (2013) 1.06
MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One (2013) 1.03
Genetic therapy for the nervous system. Hum Mol Genet (2011) 1.03
Mechanistic Roles of Noncoding RNAs in Lung Cancer Biology and Their Clinical Implications. Genet Res Int (2012) 1.03
Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol (2013) 1.02
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
MicroRNA expression and clinical outcome of small cell lung cancer. PLoS One (2011) 0.99
MicroRNA-377 inhibited proliferation and invasion of human glioblastoma cells by directly targeting specificity protein 1. Neuro Oncol (2014) 0.99
PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer (2013) 0.97
miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. Oncotarget (2014) 0.97
Nucleic acid-gold nanoparticle conjugates as mimics of microRNA. Small (2011) 0.97
Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem (2014) 0.96
miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo. Exp Cell Res (2013) 0.96
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet (2012) 0.95
MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res (2016) 0.94
Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. Cell Cycle (2013) 0.94
Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One (2011) 0.94
In-depth analysis shows synergy between erlotinib and miR-34a. PLoS One (2014) 0.93
MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia (2013) 0.93
The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. Sci Rep (2013) 0.93
MicroRNA as tools and therapeutics in lung cancer. Respir Med (2015) 0.93
MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacol Res (2013) 0.92
An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR. Sci Rep (2015) 0.92
Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett (2011) 0.92
RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel) (2013) 0.92
MicroRNAs and triple negative breast cancer. Int J Mol Sci (2013) 0.91
Preferential regulation of miRNA targets by environmental chemicals in the human genome. BMC Genomics (2011) 0.91
MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol (2013) 0.90
Role of microRNA-1 in human cancer and its therapeutic potentials. Biomed Res Int (2014) 0.90
A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-α and ERK2 that controls breast cancer proliferation and invasiveness properties. Horm Cancer (2012) 0.90
MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. Oncotarget (2016) 0.89
MicroRNAs in Breastmilk and the Lactating Breast: Potential Immunoprotectors and Developmental Regulators for the Infant and the Mother. Int J Environ Res Public Health (2015) 0.88
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. Drug Metab Dispos (2015) 0.88
MicroRNAs in Head and Neck Cancer. Int J Dent (2013) 0.88
Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis (2012) 0.88
Identification of microRNA-Like RNAs in the filamentous fungus Trichoderma reesei by solexa sequencing. PLoS One (2013) 0.87
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia (2014) 0.87
MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol (2012) 0.87
YM500v2: a small RNA sequencing (smRNA-seq) database for human cancer miRNome research. Nucleic Acids Res (2014) 0.87
miRNAs as potential therapeutic targets for age-related macular degeneration. Future Med Chem (2012) 0.87
MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J Med Res (2013) 0.86
Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells. PLoS One (2014) 0.86
Non-coding RNAs as theranostics in human cancers. J Cell Biochem (2012) 0.85
Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models. Mol Ther Nucleic Acids (2014) 0.85
MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics. Front Mol Biosci (2015) 0.85
Targeting MicroRNAs in Cancer Gene Therapy. Genes (Basel) (2017) 0.85
Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget (2015) 0.85
Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol (2012) 0.84
Creating a flexible multiple microRNA expression vector by linking precursor microRNAs. Biochem Biophys Res Commun (2011) 0.83
Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. Biochem Pharmacol (2015) 0.83
Cancer heterogeneity: origins and implications for genetic association studies. Trends Genet (2012) 0.83
MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor α: implications for cancer therapeutics. J Biol Chem (2014) 0.83
MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6. World J Surg Oncol (2013) 0.83
Epigenetic mechanisms governing the process of neurodegeneration. Mol Aspects Med (2012) 0.83
MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8. J Transl Med (2015) 0.83
MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer Res (2016) 0.82
The potential clinical applications and prospects of microRNAs in lung cancer. Onco Targets Ther (2014) 0.82
Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis. Curr Pharmacogenomics Person Med (2011) 0.82
Enrichment of A Rare Subpopulation of miR-302-Expressing Glioma Cells by Serum Deprivation. Cell J (2015) 0.82
Modulation of cancer traits by tumor suppressor microRNAs. Int J Mol Sci (2013) 0.82
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res (2015) 0.82
Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease. Mol Ther Nucleic Acids (2015) 0.82
NRP1 function and targeting in neurovascular development and eye disease. Prog Retin Eye Res (2016) 0.82
ALS and FTD: an epigenetic perspective. Acta Neuropathol (2016) 0.81
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs (2016) 0.81
Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. Biomed Res Int (2014) 0.81
Clinical Significance of MicroRNA Expression Profiles and Polymorphisms in Lung Cancer Development and Management. Patholog Res Int (2011) 0.81
Targeting miRNAs for pancreatic cancer therapy. Curr Pharm Des (2014) 0.81
Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells. Small (2014) 0.81
Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis (2014) 0.81
Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther (2014) 0.81
Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue. Small (2016) 0.81
Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics (Basel) (2013) 0.80
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Regression of murine lung tumors by the let-7 microRNA. Oncogene (2009) 2.83
Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer (2001) 1.88
Adenovirus p53 gene therapy. Expert Opin Biol Ther (2006) 1.49
Cancer complexity slows quest for cure. Nature (2008) 1.47
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J (2010) 5.43
Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet (2004) 5.25
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Surgical treatment of permanent diaphragm paralysis after interscalene nerve block for shoulder surgery. Anesthesiology (2013) 4.25
Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis (2008) 3.84
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA (2005) 3.12
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis (2006) 3.04
Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS (2002) 2.93
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Viral gastroenteritis outbreaks in Europe, 1995-2000. Emerg Infect Dis (2003) 2.79
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making (2005) 2.65
Hunting for consensus: reconciling bushmeat harvest, conservation, and development policy in West and Central Africa. Conserv Biol (2007) 2.50
Validity of the alcohol use disorders identification test in college students. Alcohol Clin Exp Res (2004) 2.30
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 2.28
Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol (2008) 2.24
International collaborative study to compare reverse transcriptase PCR assays for detection and genotyping of noroviruses. J Clin Microbiol (2003) 2.23
Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis (2007) 2.22
A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med (2015) 2.16
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Diagnosing norovirus-associated infectious intestinal disease using viral load. BMC Infect Dis (2009) 2.09
Proinflammogenic effects of low-toxicity and metal nanoparticles in vivo and in vitro: highlighting the role of particle surface area and surface reactivity. Inhal Toxicol (2007) 2.06
Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis (2011) 2.03
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother (2007) 2.02
The pulmonary toxicology of ultrafine particles. J Aerosol Med (2002) 2.02
Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology (2009) 1.88
Mumps outbreaks across England and Wales in 2004: observational study. BMJ (2005) 1.87
Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol (2010) 1.86
Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res (2007) 1.83
Personalized exposure assessment: promising approaches for human environmental health research. Environ Health Perspect (2005) 1.83
Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis (2007) 1.79
Early identification of common-source foodborne virus outbreaks in Europe. Emerg Infect Dis (2003) 1.75
Dendrodendritic inhibition and simulated odor responses in a detailed olfactory bulb network model. J Neurophysiol (2003) 1.72
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
A two-compartment mathematical model of endotoxin-induced inflammatory and physiologic alterations in swine. Crit Care Med (2012) 1.69
Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med (2002) 1.66
Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene (2003) 1.65
Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol (2003) 1.64
Diagnosing rotavirus A associated IID: Using ELISA to identify a cut-off for real time RT-PCR. J Clin Virol (2009) 1.59
Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol (2003) 1.55
Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res (2012) 1.55
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol (2011) 1.49
United States feasibility study of transcatheter insertion of a stented aortic valve by the left ventricular apex. Ann Thorac Surg (2008) 1.47
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob Agents Chemother (2011) 1.46
Learning to work together: developing academic and community research partnerships. WMJ (2004) 1.45
High-throughput RNAi screening in vitro: from cell lines to primary cells. RNA (2005) 1.45
Randomized trial of surgical cutdown versus percutaneous access in transfemoral TAVR. Catheter Cardiovasc Interv (2013) 1.45
Toric Implantable Collamer Lens for moderate to high myopic astigmatism. Ophthalmology (2007) 1.45
Indigenous hepatitis E virus infection in England: more common than it seems. J Clin Virol (2009) 1.44
Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One (2012) 1.43
The elimination of indigenous measles transmission in England and Wales. J Infect Dis (2003) 1.42
Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. Trop Med Int Health (2003) 1.42
Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin (2006) 1.41
Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther (2003) 1.41
Characterization of G10P[11] rotaviruses causing acute gastroenteritis in neonates and infants in Vellore, India. J Clin Microbiol (2004) 1.41
Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg (2007) 1.40
Tracheary element differentiation. Annu Rev Plant Biol (2007) 1.39
H3ABioNet, a sustainable pan-African bioinformatics network for human heredity and health in Africa. Genome Res (2015) 1.39
Olden times: looking back on a career at the NIEHS. Environ Health Perspect (2004) 1.38
Early qualitative risk assessment of the emerging zoonotic potential of animal diseases. BMJ (2005) 1.38
Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology (2010) 1.32
Brief physician advice for heavy drinking college students: a randomized controlled trial in college health clinics. J Stud Alcohol Drugs (2010) 1.30
Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther (2011) 1.28
miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol (2011) 1.27
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer (2006) 1.27
Cigarette smoking and associated health risks among students at five universities. Nicotine Tob Res (2009) 1.26
Risk factors associated with human infection during the 2006 West Nile virus outbreak in Davis, a residential community in northern California. Am J Trop Med Hyg (2008) 1.24
Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene (2005) 1.23
Changing patterns of rotavirus genotypes in ghana: emergence of human rotavirus G9 as a major cause of diarrhea in children. J Clin Microbiol (2003) 1.23
Development of the Global Measles Laboratory Network. J Infect Dis (2003) 1.20
Strategies for setting a national research agenda that is responsive to community needs. Environ Health Perspect (2003) 1.19
Constructs of health and environment inform child obesity prevention in American Indian communities. Obesity (Silver Spring) (2008) 1.19
Community prevalence of antibodies to human immunodeficiency virus in rural and urban Vellore, Tamil Nadu. Natl Med J India (2005) 1.18
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg Med Chem Lett (2008) 1.16
The astrocyte/meningeal cell interface is a barrier to neurite outgrowth which can be overcome by manipulation of inhibitory molecules or axonal signalling pathways. Mol Cell Neurosci (2003) 1.16
Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer (2002) 1.14
Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties. J Med Chem (2010) 1.13
Reproductive tract infections: prevalence and risk factors in rural Bangladesh. Bull World Health Organ (2002) 1.13
A cross-sectional survey of herbal remedy taking by United Arab Emirate (UAE) citizens in Abu Dhabi. Pharmacoepidemiol Drug Saf (2008) 1.11
Depression and suicide ideation among students accessing campus health care. Am J Orthopsychiatry (2011) 1.11
Impact of aerial spraying of pyrethrin insecticide on Culex pipiens and Culex tarsalis (Diptera: Culicidae) abundance and West Nile virus infection rates in an urban/suburban area of Sacramento County, California. J Med Entomol (2008) 1.10
Participatory photo mapping (PPM): exploring an integrated method for health and place research with young people. Health Place (2008) 1.10
Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res (2011) 1.09
Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother (2011) 1.09
The efficacy of a brief alcohol intervention combined with %CDT feedback in patients being treated for type 2 diabetes and/or hypertension. J Stud Alcohol (2004) 1.08
NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer (2009) 1.07
MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology (2013) 1.07
Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem (2009) 1.07
Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics (2009) 1.07
Status of global virologic surveillance for rubella viruses. J Infect Dis (2011) 1.06
Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women. J Acquir Immune Defic Syndr (2003) 1.03
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother (2010) 1.03
Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer (2006) 1.02
Sufficiently important difference for common cold: severity reduction. Ann Fam Med (2007) 1.01